Mechanical Circulatory Support: A Clinical Reality

2008 ◽  
Vol 16 (5) ◽  
pp. 419-431 ◽  
Author(s):  
Daniel Loisance

Mechanical circulatory support is becoming an alternative therapeutic option for patients in cardiogenic shock or advanced cardiac failure who cannot be improved by maximal medical therapy. More than 30 years of engineering development and clinical research have led to a level of efficacy and reliability of ventricular assist devices, which allows promotion of this approach for the most difficult patients. Uses include a gaining-time strategy as a bridge to cardiac transplantation or recovery of native cardiac function, as well as permanent support with the device. The large variety of devices permits every cardiac surgical unit, even those not used to cardiac transplantation, to propose this option to the patient. Recent experience with small silent implantable pumps suggests that the pioneering period of mechanical circulatory support is probably over, and the time has come for precise prospective trials to optimize both patient selection and the timing for utilization. In countries where cardiac transplantation has not developed, there is now an easily accessible technique for management of patients with cardiac failure.

1999 ◽  
Vol 8 (5) ◽  
pp. 324-337 ◽  
Author(s):  
K Scherr ◽  
L Jensen ◽  
A Koshal

Mechanical circulatory support is used to sustain the lives of patients awaiting cardiac transplantation who would otherwise die before a donor organ became available. Currently available ventricular assist devices used for mechanical circulatory support, risk factors and complications associated with use of these devices, and selection of candidates for treatment with mechanical support as a bridge to cardiac transplantation are reviewed. The importance of early insertion of the devices before end-organ dysfunction occurs is examined.


Author(s):  
Devon O. Aganga ◽  
Charlotte S. Van Dorn ◽  
Jonathan N. Johnson

Mechanical circulatory support (MCS) has become a critical tool for managing children with impending respiratory and cardiac failure. Although extracorporeal membrane oxygenation was classically the only form of support available for children, ventricular assist devices (VADs) are increasingly used in children. Common indications for MCS include an inability to oxygenate or ventilate that progresses to respiratory failure and cardiac failure secondary to anatomic abnormalities or primary myocardial failure. The most common contraindication for MCS is death in the near future. This contraindication may include patients with other fatal systemic diseases, patients at high risk of bleeding, or extreme prematurity. Important recent advances in VAD technology include the introduction of the Berlin Heart EXCOR device, as well as the successful use of devices for adults (e.g., the Heartmate and Heartware VADs) in larger children. Although outcomes of VAD support in children have been promising, further studies of smaller and clinically more complex children are required.


Author(s):  
David Ishizawar

Pulmonary hypertension (PH) is a heterogeneous group of diagnoses including pulmonary vascular disease, left-sided heart failure, lung disease, and thromboembolic disease. Regardless of the cause, PH is often associated with increased morbidity and mortality. In systolic heart failure, the development of irreversible PH precludes cardiac transplantation because the risk of allograft right-ventricular failure and death is increased. In these cases, left ventricular assist devices (LVADs) can provide circulatory support and the potential to reverse PH. This chapter discusses the WHO classifications of PH and the associated diagnoses, mechanisms, and medical and surgical treatments for PH. It also discusses the strategies for reversing PH, the indications for selecting patients with PH for heart transplantation, and how exposure of the donor heart to elevated pulmonary pressures can affect the recipient. In many of these challenging patients, mechanical circulatory support as a bridge to candidacy has permitted successful cardiac transplantation.


2014 ◽  
Vol 8s1 ◽  
pp. CMC.S15718 ◽  
Author(s):  
Nisha A. Gilotra ◽  
Gerin R. Stevens

Cardiogenic shock remains a challenging disease entity and is associated with significant morbidity and mortality. Temporary mechanical circulatory support (MCS) can be implemented in an acute setting to stabilize acutely ill patients with cardiomyopathy in a variety of clinical situations. Currently, several options exist for temporary MCS. We review the indications, contraindications, clinical applications, and evidences for a variety of temporary circulatory support options, including the intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), CentriMag blood pump, and percutaneous ventricular assist devices (pVADs), specifically the TandemHeart and Impella.


2021 ◽  
Vol 32 (4) ◽  
pp. 424-433
Author(s):  
Emalie Petersen

Heart failure is a leading cause of morbidity and mortality in the United States. Treatment of this condition increasingly involves mechanical circulatory support devices. Even with optimal medical therapy and use of simple cardiac devices, heart failure often leads to reduced quality of life and a shortened life span, prompting exploration of more advanced treatment approaches. Left ventricular assist devices constitute an effective alternative to cardiac transplantation. These devices are not without complications, however, and their use requires careful cooperative management by the patient’s cardiology team and primary care provider. Left ventricular assist devices have undergone many technological advancements since they were first introduced, and they will continue to evolve. This article reviews the history of different types of left ventricular assist devices, appropriate patient selection, and common complications in order to increase health professionals’ familiarity with these treatment options.


Perfusion ◽  
2020 ◽  
Vol 35 (6) ◽  
pp. 474-483
Author(s):  
Inge Köhne

Since the use of continuous flow blood pumps as ventricular assist devices is standard, the problems with haemolysis have increased. It is mainly induced by shear stress affecting the erythrocyte membrane. There are many investigations about haemolysis in laminar and turbulent blood flow. The results defined as threshold levels for the damage of erythrocytes depend on the exposure time of the shear stress, but they are very different, depending on the used experimental methods or the calculation strategy. Here, the results are resumed and shown in curves. Different models for the calculation of the strengths of erythrocytes are discussed. There are few results reported about tests of haemolysis in blood pumps, but some theoretical approaches for the design of continuous flow blood pumps according to low haemolysis have been investigated within the last years.


Sign in / Sign up

Export Citation Format

Share Document